THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST ViaCyte's implantable stem cell pouch One of the huge advantages of a stem cell agency like CIRM (not that there is anything out there quite like us, but anyway) is our ability to support projects as they progress from a great idea to a therapy actually … Continue reading Producing insulin for people who can’t
PEC-Direct
New partnership to make CIRM supported treatment for type 1 diabetes even better
ViaCyte, a regenerative medicine company long backed by CIRM, announced a partnership with CRISPR Therapeutics to increase the number of people with Type 1 Diabetes (T1D) who could benefit from their PEC-Direct therapeutic implant. Last year, CIRM granted ViaCyte $20 million to facilitate development of PEC-Direct, a device that both transplants pancreatic progenitor stem … Continue reading New partnership to make CIRM supported treatment for type 1 diabetes even better
The Stem Cellar 